Searchable abstracts of presentations at key conferences in endocrinology

ea0035p551 | Endocrine tumours and neoplasia | ECE2014

Evaluation of vegf and endocan/esm-1 expression in pnets and correlation with Ki67 and prognosis

Lugli Francesca , Iacovazzo Donato , Lanza Paola , Inzani Frediano , Waure Chiara De , Rindi Guido , Marinis Laura De

Endocan has been reported as specific of endothelial tumor cells and was shown to be expressed by tip cells during angiogenesis process.The principal aims of the study are the assessment of immunohistochemical VEGF and Endocan expression in functioning and non functioning pNETs and the comparison of these markers with clinical features, Ki67 and TNM staging.We collected a total number of 79 pNETs surgical specimens for immunohistoc...

ea0035p576 | Endocrine tumours and neoplasia | ECE2014

Correlation between atypical pituitary adenomas and Ki-67 Li: clinical and prognostic aspects

Chiloiro Sabrina , Bianchi Antonio , Giampietro Antonella , Iacovazzo Donato , Trapasso Barbara , Piacentini Serena , Tartaglione Linda , Lugli Francesca , De Marinis Laura

Introduction: In 2004, the WHO defined atypical pituitary adenomas (APAs) those with Ki-67 >3%, excessive p53 expression and increased mitotic activity. The usefulness of this classification is still controversial.Aim: To compare the clinical and prognostic features in a series of typical and atypical pituitary adenomas.Materials and methods: We retrospectively reviewed 343 consecutive PAs. APAs represented 18.7% of the cases. ...

ea0035p549 | Endocrine tumours and neoplasia | ECE2014

Efficacy of lanreotide autogel in men1-related gastrinomas: a case series

Iacovazzo Donato , Lugli Francesca , Bianchi Antonio , Capoluongo Ettore , Lucci-Cordisco Emanuela , Persiani Roberto , Doglietto Giovanni Battista , Pontecorvi Alfredo , Rindi Guido , De Marinis Laura

GEP NETs, especially gastrinomas, occur in 40–70% of MEN1 patients and represent the main cause of death in these patients.We aim to investigate the efficacy of lanreotide autogel (ATG) in the treatment of MEN1-related gastrinomas.We report a monocentric series of seven MEN1 patients (three M, and four F) treated with lanreotide ATG (120 mg/4 weeks) for a mean period of 62.1 months. Plasma gastrin levels have been measured at ...

ea0035p937 | Pituitary Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2014

IGF1 response to rhGH in adult GHD: role of GH receptor (GHR) isoforms

Bianchi Antonio , Tartaglione Linda , Giampietro Antonella , Milardi Domenico , Angelini Flavia , Mormando Marilda , Lugli Francesca , Piacentini Serena , Grande Giuseppe , Iacovazzo Donato , Chiloiro Sabrina , Pontecorvi Alfredo , Marinis Laura De

The IGF1 response to recombinant human growth hormone (rhGH) showed some individual variability and the responsible factors for this behavior remain unknown. Some studies have emphasized the possible role of isoforms of the GH receptor (GHR), showing conflicting results.Therefore, we investigated the possible influence of the isoforms of the GHR to the diagnosis of GHD and in determining adult hormone replacement therapy responsiveness.<p class="abst...

ea0034p425 | Thyroid | SFEBES2014

RET mutation negative familial medullary thyroid carcinoma: four families and literature review

Iacovazzo Donato , Morrison Patrick , Foulkes William , Ross Douglas , Lugli Francesca , Gabrovska Plamena , Lucci-Cordisco Emanuela , Neri Giovanni , Marinis Laura De , Korbonits Marta

Approximately 25% of the reported cases of MTC are familial. Familial MTC can occur as part of MEN2-syndrome or as familial MTC alone (fMTC) defined as more than ten carriers in the kindred, or multiple carriers or affected members over the age of 50 with an adequate medical history excluding pheochromocytoma. The vast majority of MEN2 families (98%), as well as fMTC kindreds (88%) harbour a RET mutation. In MEN2A, mutations at codon-634 (exon-11) account for 85% of all mutati...

ea0032p561 | Endocrine tumours and neoplasia | ECE2013

Everolimus treatment in a series of patients with advanced neuroendocrine tumors

Iacovazzo Donato , Lugli Francesca , Plastino Francesca , Schinzari Giovanni , Bianchi Antonio , Fusco Alessandra , Rindi Guido , Pontecorvi Alfredo , De Marinis Laura , Barone Carlo Antonio Mario

Introduction: Everolimus is an oral mTOR inhibitor that exerts antineoplastic effects inhibiting cell proliferation, survival and angiogenesis. Its activity in advanced neuroendocrine tumors (NETs) has been demonstrated in controlled trials and everolimus was approved by the FDA for the treatment of progressive, advanced pNETs in May 2011.Materials and methods: We treated with everolimus, at the dosage of 10 mg once daily, 14 patients with advanced, prog...

ea0032p874 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2013

Factors Affecting Prognosis in a Series of Acromegalic Patients

Fusco Alessandra , Bianchi Antonio , Giampietro Antonella , Iacovazzo Donato , Lugli Francesca , Chiloiro Sabrina , Piacentini Serena , Tartaglione Linda , Doglietto Francesco , Anile Carmelo , Maira Giulio , De Marinis Laura

Introduction: The main goal in the treatment of acromegaly is achieving biochemical and tumor mass control. Therapeutic options include surgery, medical treatment and, in selected cases, radiotherapy. A GH receptor (GHR) variant that differs for the genomic retention or exclusion (d3GHR) of exon 3 is present in about 50% of general population and its presence is related to a greater sensitivity to GH.Materials and methods: We describe a series of 118 pat...

ea0016p149 | Clinical cases | ECE2008

Giant myelolipoma in a patient affected by 17-α-hydroxylase deficiency and β-thalassemic trait

Sacco Eugenia , Fusco Alessandra , Bianchi Antonio , Lugli Francesca , Tartaglione Linda , Ricerca Bianca Maria , Danza Francesco , Doglietto Giovanni , Pontecorvi Alfredo , De Marinis Laura

Myelolipomas are rare benign tumours resulting from myeloid and adipose mature cells proliferation, both elements have a clonal origin from a common precursor. Myelolipomas predominantly involve the adrenal gland but may develop in extra-adrenal sites. They are hormonally inactive but may coexist with active diseases such as adrenogenital syndrome. They are often asymptomatic but rarely they cause symptoms due to their size or spontaneous retroperitoneal haemorrhage. The myelo...

ea0044p249 | Thyroid | SFEBES2016

ESR2 mutations in RET mutation-negative familial medullary thyroid carcinoma

Afghan Wazir K. , Iacovazzo Donato , Alevizaki Maria , Foulkes William , Lugli Francesca , Druce Maralyn , Dutta Pinaki , Dang Mary N. , Gabrovska Plamena , Morrison Patrick J. , Owens Martina , Ellard Sian , Sampson Julian , De Marinis Laura , Korbonits Marta

Introduction: Approximately 25% of medullary thyroid cancer (MTC) cases arise in a familial setting, either as MEN2 or fMTC. While most of these are caused by mutations in the RET gene, a few families have unidentified mutations. Recently, a frameshift mutation in the ESR2 gene (coding oestrogen receptor beta) was found in a family with RET-negative fMTC associated with C-cell hyperplasia. In vitro, transfection of mutant ESR2 led t...